Entrada Therapeutics (TRDA) said Monday it has received authorization from UK regulators to start a phase 1/2 multiple ascending dose study of ENTR-601-44 for the potential treatment of certain types of Duchenne muscular dystrophy.
The study will consist of two parts, with part A evaluating safety, pharmacokinetics, and pharmacodynamics in about 24 patients using doses from 6 mg/kg to 18 mg/kg every six weeks. Part B will further evaluate the optimal dose established in part A, the company said.
The authorization follows the completion of a phase 1 study in which ENTR-601-44 showed a favorable safety profile with no serious adverse events, or changes in trends of vital signs, the company said.
The study is expected to begin in Q2, the biopharmaceutical company said.
Price: 13.50, Change: +0.06, Percent Change: +0.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.